NYU Langone Health | Strategic Alliance Partnership

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

Although her recent study acknowledges potential differences between White and non-White patients with psoriatic arthritis (PsA), Rebecca Haberman, MD, NYU Langone Health, emphasizes the need for further research to understand what these differences are and why they occur.

Recognizing psoriasis and psoriatic arthritis (PsA) in non-White patients is the first step toward providing more equitable care for those of all backgrounds with PsA, according to Rebecca Haberman, MD, of NYU Langone Health.

Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.

February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.

In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks on his hoped-for top health care priorities under the incoming administration.

In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome treatment resistance in non–small cell lung cancer.

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

At our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Brita Roy, MD, MPH, MHS, spoke on improving cancer health outcomes through community-clinical partnerships.

In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

March 1 saw the FDA grant full approval to amivantamab plus chemotherapy for first-line use in patients who have non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, converting the May 2021 accelerated approval for this treatment in the second line.

The approval converts the May 2021 accelerated FDA approval for second-line treatment of non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations to a full approval in the first line following results from the phase 3 PAPILLON study.

Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.

This year’s top 5 most-listened to podcasts included topics on digital health solutions, cardiology, value-based care initiatives, and oncology.

Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.

Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Mary Pat Gallagher, MD, of NYU Langone Health, explains her research documenting new onset diabetes and diabetic ketoacidosis (DKA) throughout the COVID-19 pandemic.

An experimental compound prevents the virus that causes coronavirus disease 2019 (COVID-19) from entering human airway cells, a new study finds.

Video doctor visits limit spread of disease, help determine health risks to patients.

Most people with systemic lupus erythematosus and inflammatory arthritis, who use medications that make them immunosuppressed, are not necessarily at greater risk of hospitalization from coronavirus disease 2019 (COVID-19), according to 2 studies.